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The  International  Cancer  Benchmarking  Partnership  (ICBP)  was  initiated  by  the  Department
of Health  in England  to  study  international  variation  in  cancer  survival,  and  to inform  pol-
icy to improve  cancer  survival.  It is a research  collaboration  between  twelve  jurisdictions
in six  countries:  Australia  (New  South  Wales,  Victoria),  Canada  (Alberta,  British  Columbia,
Manitoba,  Ontario),  Denmark,  Norway,  Sweden,  and  the United  Kingdom  (England,  North-
ern  Ireland,  Wales).  Leadership  is  provided  by policymakers,  with  academics,  clinicians  and
cancer  registries  forming  an  international  network  to  conduct  the research.  The  project  cur-
rently  has  ﬁve  modules  examining:  (1)  cancer  survival,  (2)  population  awareness  and beliefs
about cancer,  (3)  attitudes,  behaviours  and  systems  in  primary  care,  (4)  delays  in diagno-
sis and  treatment,  and  their  causes,  and  (5)  treatment,  co-morbidities  and  other  factors.
These modules  employ  a  range  of  methodologies  including  epidemiological  and  statistical
analyses,  surveys  and  clinical  record  audit.  The  ﬁrst  publications  have  already  been  used  to
inform  and  develop  cancer  policies  in  participating  countries,  and  a  further  series  of  pub-
lications  is under  way.  The  module  design,  governance  structure,  funding  arrangements
and  management  approac
tional comparisons  of  hea
of  immediate  relevance  to
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1. Background to and aims of the International
Cancer Benchmarking Partnership
1.1. Introduction and aims
The International Cancer Benchmarking Partnership
(ICBP) is a collaboration of policymakers, researchers and
clinicians from six countries: Australia, Canada, Denmark,
Norway, Sweden and the United Kingdom. The initiative
for the ICBP came from the English Department of Health
(DH). Survival from many cancers in England and the UK
is lower than in comparable countries [1–5]. Poorer cancer
survival can reﬂect a pattern of later presentation or diag-
nosis of cancer, because more advanced cancers are difﬁcult
to treat successfully. The comparatively low one-year sur-
vival in the UK suggests that late diagnosis may  be a major
factor. It is unclear whether patients present to health care
later in the UK than elsewhere, or whether they are not
being referred adequately by GPs in the primary care sec-
tor, or not being effectively investigated in secondary care.
In order to address these questions and to examine the role
of treatment variation in international differences in sur-
vival, an innovative international study of cancer survival
was initiated.
The key aims of the ICBP are to update existing stud-
ies of international variation in cancer survival and to
explore reasons for the differences that have been reported.
Although the leadership for the ICBP has come from poli-
cymakers, close involvement of academics and clinicians at
every stage has been essential. The work has involved many
new approaches and analyses to ensure international com-
parability of datasets and valid benchmarking [6,7]. This
article outlines the background to the ICBP, the method-
ologies, the results and the lessons that have been learned
to date.
1.2. Background
Population-based cancer registration has enabled use-
ful international comparisons of key cancer measures,
including incidence, prevalence and survival. In particu-
lar, cancer survival is a key measure of health system
performance, because variations in survival point to poten-
tially avoidable deaths among jurisdictions with lower
survival [8]. International comparisons of cancer survival
have prompted new health policy in countries with low
survival, and they help to inform global cancer control
strategies [9–13]. However, decisions on how to reform
the national provision of cancer care have often relied
on other considerations than a sound knowledge-base.
Table 1
Major international studies of cancer survival.
Period of
diagnosis
Last year of
follow-up
No of countries and canc
EUROCARE-1 1978–1984 1989 30 cancer registries in 12
EUROCARE-2 1985–1989 1994 45 cancer registries in 17
EUROCARE-3 1990–1994 1999 67 cancer registries in 22
CONCORD 1990–1994 1999 101 cancer registries in 3
EUROCARE-4 1995–1999 2003 83 cancer registries in 23
ICBP 1995–2007 2007 20 cancer registries in si112 (2013) 148– 155 149
Therefore, there is a need for comprehensive knowledge
about the complex processes in the cancer pathway, from
the very ﬁrst symptoms of cancer in a person to their
eventual investigation, treatment and care in the health
system.
The major international studies of cancer survival are
subject to three criticisms. Firstly, the delay between the
period during which the patients were diagnosed and the
publication of the report ranges from 9 to 14 years, during
which interval signiﬁcant changes in health policy or treat-
ment may  occur. These studies provide useful insights into
recent patterns of survival, but may  not provide contem-
porary information of direct relevance to policy-makers
because they can rarely reﬂect the impact of recent national
and local initiatives [12–15] (see Table 1).
A second criticism is the population coverage of the can-
cer registries. In some regions, such as Scandinavia and
the United Kingdom, there is national cancer registration.
In other countries population-based cancer registries only
cover a small proportion of the national population (e.g.
Germany 1%, France 11%, Spain 14%, Italy 25%), albeit with
comprehensive population coverage in the registry areas.
Thirdly, international comparisons may  quantify differ-
ences in cancer survival, but do not usually explain why
they exist. For example, are they due to later presentation of
cancers in countries with low survival, leading to reduced
access to optimal treatment, hence prompting strategies
to improve earlier diagnosis? Both CONCORD and EURO-
CARE groups have conducted “high-resolution” studies to
look in detail at disease, patient and treatment factors that
may  inﬂuence survival. These indicate that more advanced
stage at diagnosis and the quality of treatment both have an
impact on international differences in survival [17–20]. For
some cancers (e.g. breast) most of the longer-term survival
variation in Europe is due to low 1-year survival, because
ﬁve-year survival amongst patients who survive one year
is similar to the European average [21]. This suggests that
low breast cancer survival in the UK is mainly attributable
to late diagnosis or advanced stage. For other tumours, such
as the kidney, both 1-year survival and 5-year survival con-
ditional on survival to one year are low, suggesting both late
diagnosis and treatment differences.
With this background, the National Cancer Director
for England, Professor Sir Mike Richards, established the
International Cancer Benchmarking Partnership in 2009
(www.icbp.org.uk) [22]. The partnership aims to identify
and explain the relative contribution of different factors to
cancer survival variations between high-income countries,
so that the ﬁndings can be used to inform cancer policy and
improve cancer survival.
er registries in study Date of
publication
Main publication
 European countries 1995 Berrino et al. (1995) [1]
 European countries 1999 Berrino et al. (1999) [2]
 European countries 2003 Berrino et al. (2003) [3]
1 countries 2008 Coleman et al. (2008) [5]
 European countries 2009 Berrino et al. (2007) [4]
x countries 2011 Coleman et al. (2011) [16]
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.3. Identifying partners
To develop an international collaboration of countries,
t was necessary to establish a group that was small enough
o be manageable and which included countries that rep-
esented a range of cancer survival, and were comparable
o the UK on key health policy issues and were keen
o understand and improve cancer outcomes. Four key
riteria were established: ﬁrst, the countries should have
igh-quality and long-standing population-based cancer
egistration with good coverage, to ensure that cancer sur-
ival results were representative of national outcomes.
econd, there should be universal access to health care,
ecause health systems with substantial components of
rivate and/or insurance-based healthcare will have dif-
erent policy needs to those with more centrally funded
ystems. Third, countries should have broadly comparable
ealth and broadly similar expenditure on healthcare pro-
ision as a proportion of GDP. Finally, countries should be
illing to commit signiﬁcant time, enthusiasm and funding
o participate in an international collaboration.
After initial scoping work by the Department of Health
n England (DH) Professor Richards, and a Programme
eview Board that was formed, invited countries to partic-
pate. Six countries encompassing 12 jurisdictions agreed
o join at the outset: Australia (New South Wales and Vic-
oria), Canada (Alberta, British Columbia, Manitoba and
ntario), Denmark, Norway, Sweden and the United King-
om (England, Northern Ireland, and Wales) with a total
opulation in 2009 of 111 million (81% of the total national
opulations) (see Appendix). In all jurisdictions there is
00% cancer registration and population-based breast can-
er screening.
.4. Research aims
The ICBP aims to deﬁne and explain international vari-
tion in cancer survival, using a combination of analyses
f routine data and primary research. The decision was
aken to look speciﬁcally at a small number of cancers
hat might highlight reasons for international variations
n survival and represent different pathways to diagno-
is. Four cancers were selected: breast, colorectal, lung,
nd ovarian cancer. Breast, colorectal and lung cancers
re common and contribute a large share of the cancer
urden in developed countries, as well as exhibiting signif-
cant survival differences between countries. Breast cancer
lso had well-established mammographic screening pro-
rammes in most participating countries (not Denmark).
varian cancer is a less common cancer with a complex
iagnostic pathway and large international variations in
ne and ﬁve-year survival.
Previous research into cancer survival has identiﬁed a
ange of factors that contribute to international differences
23]. These include:Stage at diagnosis and quality of treatment.
Delay in diagnosis and treatment.112 (2013) 148– 155
• Treatment differences, including access to surgery, radio-
therapy and cancer drugs, and the co-ordination and
organisation of treatment.
• Patient factors, including co-morbidity and age.
• Tumour and physiological/biological factors.
Many studies have found evidence to suggest that com-
binations of some or all of these factors explain survival
differences [17–19,24–26].
2. Methodology
The ICBP research programme is divided into ﬁve mod-
ules. Module 1 is the core epidemiological analysis. Cancer
registry data have been used to quantify survival dif-
ferences between 1995 and 2007, thus extending and
updating previous studies of international differences in
survival under EUROCARE and CONCORD [16]. Analyses
of survival by stage at diagnosis and by treatment are in
progress, again using registry data. This module should help
establish the extent to which variations in stage at diagno-
sis and/or treatment can explain international differences
in cancer survival.
Modules 2, 3 and 4 are investigating various aspects of
time intervals (delay) in cancer diagnosis and treatment.
Time intervals can be broken down into different stages,
such as patient, primary care and secondary care based on
speciﬁc milestones (Fig. 1) [27].
Module 2 builds on the existing evidence that patient
interval to presentation contributes to delay in diagno-
sis and thus poorer survival, and that factors inﬂuencing
patient delay include lack of awareness of cancer symp-
toms, negative beliefs about cancer, and barriers (both
perceived and real) to seeking health care [28,29]. Through
a telephone survey of people aged 50 years or more, it
tests the hypotheses that people living in countries with
poorer cancer survival have lower cancer awareness, more
negative beliefs about cancer, and more barriers to presen-
tation. The ﬁndings here will be compared to the ﬁndings
in module 4 to compare patient intervals with awareness.
Module 3 explores primary care delay, based on the
hypothesis that it is associated with poorer survival, and
that the factors inﬂuencing primary care delay include the
knowledge and attitudes of primary care physicians, the
behaviour of primary care physicians regarding examina-
tion, investigation and referral, and differences in primary
care systems such as referral pathways and access to inves-
tigations in primary care [29–32]. This module incorporates
a web-based survey of general practitioners: it includes
a series of exercises in which the GP is asked to set out
the clinical response (investigations, referral, etc.) in hypo-
thetical patient vignettes, and direct questions. It also
includes an exercise to map  differences in primary care sys-
tems through desk research and expert input. This module
should provide evidence to test hypotheses that interna-
tional differences in knowledge, attitudes and behaviours
of primary care physicians are associated with interna-
tional differences in cancer survival.
Module 4 aims to gather data on the time intervals
experienced by cancer patients from their ﬁrst symptom to
their diagnosis and ﬁrst treatment, testing the hypothesis
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s in cancFig. 1. Categorisation of interval
that longer time intervals will be experienced by patients
in countries with lower cancer survival. Data are being
collected by postal survey of recently diagnosed cancer
patients, combined with surveys of the same patients’ pri-
mary care and specialist doctors. The instruments have
been developed from surveys previously conducted in
some member countries, and they adhere to a recent inter-
national methodological consensus regarding best practice
in the measurement of time intervals in the cancer patient
pathway [27].
Plans for module 5 are under development, but the
intention is to build on the data collected through module
1 to explore routinely available data on patients’ pathways
through diagnosis and treatment, and to investigate how
treatment differences may  contribute to differences in can-
cer survival.
3. Governance and funding
A deﬁning feature of the ICBP is that it is a collabo-
rative partnership between policymakers, researchers and
clinicians. The formal governance structure for the ICBP is
shown in Fig. 2.
An international Programme Board, chaired by Profes-
sor Richards, includes representatives of the governments
or cancer agencies in each country. The Board provides
oversight and strategic direction. Many Board members
have a clinical or academic background in cancer prior to
or alongside their current senior administrative roles. The
Board meets via teleconference every one to two months to
review progress and make major decisions such as approv-
ing study protocols and contributing to draft publications.
Day-to-day management and co-ordination is provided
by a sub-contracted Programme Management function,
initially the responsibility of McKinsey & Company, but
transferred to Cancer Research UK during 2010. This change
was made to reduce management costs and to engage aer diagnosis and treatment [27].
specialist charity with wide experience in managing cancer
research and in contributing to cancer policy.
The Programme Management team acts a secretariat to
the Board and working groups, manages the ﬁnances and
contracts involved in the project, and supports the module
chairs and local teams in their duties. A Programme Review
Board in England meets monthly to hold the Programme
Management team to account for progress and resolve day-
to-day management issues as necessary.
Each module is led by a central academic team compris-
ing experts in the relevant disciplines, appointed by the
Programme Board. The central team comprises the prin-
cipal investigators and lead researchers for each module.
Each central team works with academic leads identiﬁed
by Programme Board members in each of the participating
jurisdictions. The central team and local leads have worked
together to develop the study protocols and carry out the
research.
Many of the academics involved are also practising cli-
nicians. However, to provide further formal clinical input,
particularly into the interpretation of registry data under
module 1, the ICBP also has a clinical committee of expert
senior oncologists and cancer surgeons in each cancer type,
with membership from all countries.
Module 1 was  funded by the Department of Health and
the National Cancer Action Team in England, after a com-
mitment made in the Cancer Reform Strategy for England
[15]. Modules 2–5 are funded collectively, with each partic-
ipating jurisdiction contributing a proportion of the costs.
4. Results
As of March 2013, eight articles have been published
or are in press, including two  methodological papers
[6,7,16,33–38].
The ﬁrst paper from the ICBP was published in The
Lancet in 2011 and received local and international media
152 J. Butler et al. / Health Policy 112 (2013) 148– 155
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overage. Survival had improved in all countries for all four
ancers from 1995 to 2007. However the gap in survival
etween the best performing countries (Australia, Canada,
nd Sweden) and the lowest (UK and Denmark) remained
argely unchanged, other than for breast cancer, where
t had narrowed. Norway had intermediate survival (see
ppendix) [16].
Examination of survival by stage proved complex,
ecause the participating countries use several different
ystems of classifying and coding stage at diagnosis, and
he completeness of data on stage at diagnosis was  vari-
ble and often low, especially for patients diagnosed before
000. This constrained the number of data sets that could
e included in international comparisons of stage-speciﬁc
urvival. It proved necessary to devise a new algorithm to
armonise the disparate classiﬁcations of stage, in order
o achieve comparable estimates of the distribution of
oth stage at diagnosis and stage-speciﬁc survival. The
lgorithm has been published as a guide to help improve
nternational comparisons of cancer survival by stage,
long with recommendations to improve the quality and
nternational comparability of stage data [6].
The impact of stage at diagnosis on international differ-
nces in cancer survival has been examined. For ovarian
ancer, survival in the UK was particularly low for women
iagnosed at an advanced stage, although the stage distri-
ution in the UK did not appear to be worse than countries
ith higher survival. This may  be explained by later diagno-
is of advanced stage disease or inferior treatment quality
n the UK. In Denmark, by contrast, the distribution of stage
as more adverse, potentially due to differences in diag-
ostic delay or staging procedures [33].
For lung cancer, survival in the UK was lower than in
he other countries at each stage of disease, both for small-
ell and non-small cell lung cancer, suggesting incompleteture of the ICBP.
access to optimal treatment at each stage of disease. The
proportion of patients diagnosed at an early stage of disease
was  also lower in the UK and Denmark, suggesting that
differences in both stage at diagnosis and the diagnostic
investigations to determine the stage could also contribute
to lower overall survival [34].
For breast cancer, one-year survival for women with
early (stage I) disease was close to 100% in all six
countries. International differences in survival for women
with advanced disease were wide, however, ranging from
53% in the UK to 67% in Sweden at one year and 28%
(UK) to 42% (Sweden) at three years [35]. In Denmark,
early diagnosis was  much less common than in the other
countries, but stage-speciﬁc survival was  similar, suggest-
ing that comparatively low overall survival was  primarily
due to late diagnosis: Denmark was the only country not to
have implemented nation-wide mammographic screening
before 2006. The low survival was  particularly marked for
older women in the UK. Taken together, the ﬁndings sug-
gest that women  diagnosed in the UK at age 70 years or
older, and those with advanced disease at diagnosis, are
not being treated as aggressively as in other countries.
The patterns of stage at diagnosis for colorectal cancer
varied widely between the six countries, with more late
disease in Denmark and more regional disease in Australia,
Norway and the UK [36]. Differences in one-year survival
were also wide, ranging from 67 to 71% for colon can-
cer in the UK and Denmark to around 80% in the other
countries. The pattern was  similar for rectal cancer, but
the differences were less marked, with one-year survival
around 75–79% in Denmark and the UK, and 82–84% in the
other countries. Stage-speciﬁc survival at one and three
years was  low in the UK for each stage of disease. These
patterns suggest that stage at diagnosis explains some of
the international differences in colorectal cancer survival,
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with more advanced disease contributing to comparatively
low overall survival in Denmark, but the differences in
stage-speciﬁc survival at each stage of disease also suggest
unequal access to optimal treatment, particularly in the UK.
Module 1 studies have also highlighted deﬁciencies or
variations in cancer registration in several jurisdictions,
leading to programmes to improve recording. In England,
the eight regional cancer registries are migrating to a new
system of cancer registration and data acquisition that will
include stage and treatment information – English National
Cancer Online Registration Environment (EnCORE). Cancer
Council Victoria has also started a programme to improve
the recording of stage at diagnosis.
Module 2 papers reported little difference in awareness
of cancer symptoms and beliefs about cancer outcomes
between the countries. However, the study revealed sig-
niﬁcant differences in people’s barriers to symptomatic
presentation. Being worried about wasting the doctor’s
time was particularly common in the UK (34%) and least
common in Sweden (9%). Embarrassment about going to
the doctor with a symptom that might be serious was most
commonly reported in the UK (15%) and least in Denmark
(6%). The study also found that awareness of the risk of can-
cer being higher in older people varied signiﬁcantly across
countries, being lowest in Canada (13%) and the UK (14%)
and highest in Sweden (38%) [7,37].
Further papers from subsequent modules including sys-
tem mapping in primary care are in press or being drafted.
5. Overall ‘methodological’ lessons learned about
conducting a partnership in this way
To the best of our knowledge, there has been no simi-
lar collaboration of equivalent magnitude between policy
makers, academics, cancer registries and clinicians. This
has led to both signiﬁcant beneﬁts and challenges. Beyond
the particular methodological issues that have arisen for
each study within the ICBP, there are also methodological
and practical challenges and lessons that emerge from the
ambitious approach of the ICBP as a whole.
One practical issue has been the lack of opportunities
for face-to-face meetings and the difﬁculties of scheduling
teleconferences at convenient hours for all participants.
The major challenges however have been timescales and
funding. The co-ordination of a programme of work as
complex as the ICBP requires detailed management, with
signiﬁcant associated costs. The ICBP studies therefore cost
money to the countries involved even before the research
protocols are ﬁnalised, since the academic teams and the
Board need to be supported throughout this process.
Throughout every part of the programme, the modules
have taken longer than initially anticipated by the Board.
This is due to a number of different factors. The original
timescales proposed were arguably too ambitious and did
not factor in sufﬁcient time for the collaborative intellec-
tual, design and testing phases that were necessary in the
early phases of each module. Each module has also faced
unforeseen challenges as the work has progressed: this
is perhaps typical of complex international comparative
research in which new research instruments and method-
ologies are required to answer its questions. Module 1112 (2013) 148– 155 153
faced considerable challenges in the availability, compa-
rability and quality of data on cancer stage. Further delays
have occurred with work progressing at signiﬁcantly differ-
ent paces in different countries/jurisdictions, depending on
available resources – in particular local academic resource
to develop the local protocols necessary to establish the
feasibility of each study for that country.
Given the programme management structure adopted
by the ICBP, these delays cost money and so are arguably
more directly problematic than they would be with tra-
ditional research. Related to this, the funding structure
adopted for modules 2–5 – where countries pay their share
of costs once they have decided that they are deﬁnitely able
to participate – has meant that countries ready to sign up
early (and in some cases needing to sign up at particular
times to ensure funding from a particular ﬁnancial year
remained available) can be unclear as to the total cost since
the ﬁnal number of participating countries is not known
and may  not be for some considerable time. Modules
would have been much easier if there had been cross-
government commitment at the outset, but this would
have been difﬁcult to obtain as we  could not provide a
deﬁnite protocol and for many jurisdictions 3rd sector
cancer charities provided signiﬁcant funding. A further
challenge is that the countries with lower survival, gener-
ally Denmark and the UK, may  seem to have more to gain
than high-performing countries. Ultimately all involved
with the ICBP have learned lessons about how to conduct
such a partnership and we  believe the current approach is
an appropriate model for similar undertakings.
Fundamentally, many of these challenges relate to the
fact that there are natural motivations and practical factors
that tend towards the ICBP progressing slowly, but also a
need to push the work on as quickly as possible to minimise
costs and deliver results in a timescale most useful to pol-
icymakers. On the one hand, the ICBP has a strong ethos of
shared decisions and collaboration, and of recognising and
adapting to the different needs, resources and issues faced
in each participating country, in order to make the work
as inclusive and relevant as possible for all involved, and
to give sufﬁcient time for all relevant methodological chal-
lenges to be fully discussed, tested and resolved to ensure
the academic rigour of the work. On the other hand how-
ever, the ICBP does seek to achieve results in a timely way,
with value for money. To some extent, a requirement on all
countries to provide some funding upfront and a more real-
istic assessment of likely timescales involved could help
any future similar endeavours avoid some of the challenges
faced by the ICBP.
In terms of beneﬁts, the continued leadership and col-
laboration of senior policymakers at the Programme Board
helps to ensure that the research questions being posed
will be directly useful to policymakers in each country, and
helps encourage the policymakers to act on and use the
ﬁndings and recommendations from the research. Given
the expertise of many of the Board members, the Board
also provides invaluable expert review, ensuring that the
studies are not only relevant to policy, but also rigorously
designed and academically robust.
Running a set of concurrent studies that collectively
tackle the priority research questions for policymakers also
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rovides potential for the results to be considered as a
hole, alongside each other. By testing a range of differ-
nt hypotheses for what might be causing international
ifferences in cancer survival, policymakers are more able
o build up a sense of where policy interventions might
rovide the greatest return in terms of survival gain.
A further important beneﬁt is the building of enduring
artnerships, both at Board level and amongst the research
eams. The partners have been very committed to contin-
ing with the work, recognising potential beneﬁts to their
wn jurisdictions and to other countries in the future. The
CBP has created an interest network, which it is hoped
ill outlast the current studies. Academic teams involved
re already planning further analyses and collaborations
ased on the work done so far, and the Programme Board
as begun to discuss the potential for further comparative
ork looking at other types of cancer and other research
uestions. These include examining the costs of cancer,
se of diagnostics, hospital beds, chemotherapy and qual-
ty of life. This model of international collaboration may  be
f interest for other disease types such as cardiovascular
isease.
The work of the ICBP has already contributed to pol-
cy development in the UK including the setting of levels
f Ambition for the NHS Outcomes framework [38,39]. In
anada the module 2 population awareness survey was
xtended to all provinces to ensure a national picture of
ublic perceptions was obtained. Lung cancer survival vari-
tion in Canadian provinces had led to new initiatives to
educe the time from diagnosis to surgical treatment. In
ales, England and Victoria lack of staging and treatment
nformation has led to policies to improve the quality of
egistry recording of stage [38,40].
ppendix A.
Programme Board:  Ole Andersen (Danish National Board
f Health, Hospital Services and Emergency Management,
openhagen, Denmark), Søren Brostrøm (Danish National
oard of Health, Hospital Services and Emergency Manage-
ent, Copenhagen, Denmark), Heather Bryant (Canadian
artnership Against Cancer, Toronto, ON, Canada), David
urrow (Cancer Institute New South Wales, NSW, Sydney,
ustralia), Anna Gavin (Northern Ireland Cancer Reg-
stry, Queens University, Belfast, UK), Gunilla Gunnarsson
Swedish Association of Local Authorities and Regions,
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